Title: Oligonucloetides and Methods Using [the] Same for Treating Cox-II-Associated Diseases. Number: 20040110698. Filed: Dec. 10, 2002. Lead Inventor: Mordechai Shemesh, Bar-Ilan University.
The patent application, its abstract states, covers “a small interfering duplex oligonucleotide comprising a 15- to 30-base pair sequence being at least 90 percent identical to a contiguous nucleic acid sequence of Cox-II, as determined using the GCG BestFit software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 50, length weight equals 3, average match equals 10, and average mismatch equals 9.”
The application specifically claims the use of these oligonucleotides to treat subjects with any of the following conditions: inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and inflammation due to endotoxin exposure or endotoxic shock; reproductive diseases including premature labor, pre-term premature rupture of the fetal membranes, premature effacement and dilation and endometriosis; respiratory diseases including ARDS, kidney diseases including glomerulitis, and glomerulonephritis; digestive diseases including chronic liver disease, ulcerative colitis; cell proliferative disorders including cancer; and neuerodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, stroke, and pain.
Title: Active Interferometric Signal Analysis in Software. Number: 20040111219. Filed: July 9, 2003. Inventor: Sandeep Gulati, ViaLogy.
According to the patent application’s abstract, the invention covers techniques for “performing active interferometric signal analysis in software [which exploit] … expressor functions designed to extract spectral invariants of events of interest associated with an arrayed platform device used to detect the signal pattern to be analyzed.“
This pattern can be generated from devices including RNAi-arrays, the application states.
Title: Methods for Treating Patients and Identifying Therapeutics. Number: 20040110712. Filed: Aug. 26, 2003. Inventor: Sanford Markowitz, Case Western Reserve University.
The patent application’s abstract states that the invention comprises “molecular markers for categorizing the neoplastic state of a patient, [as well as] methods for using the molecular markers in designing, screening for, and targeting [therapeutics].”
The application specifically claims a method of inhibiting the growth or proliferation of a colon neoplasia in a subject by administering an agent, including an siRNA probe, that decreases the amount of a polypeptide present in or produced by the colon neoplasia.
Title: Nucleic Acid Injected into Hepatic Vein Lumen and Delivered to Primate Liver. Number: 20040110697. Filed: Dec. 5, 2002. Lead Inventor: Jon Wolff, Mirus.
According to the patent application’s abstract, the invention is a process for “obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein.”
Specially claimed by the patent application is the process of putting an siRNA into a solution, which is then inserted into the lumen of a hepatic vein.
Title: Conjugates and Compositions for Cellular Delivery. Number: 20040110296. Filed: April 30, 2003. Lead Inventor: Chandra Vargeese, Ribozyme Pharmaceuticals (Sirna Therapeutics).
The patent application, states its abstract, covers an invention featuring “conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipids, peptide, and human serum albumin-derived conjugates of biologically active compounds including antibodies, antivirals … antisense, dsRNA, siNA, siRNA, triplex oligonucleotides … and aptamers.”
Title: Cells in which Activity of the Protein Involved in Transportation of GDP-Fucose is Reduced or Lost. Number: 20040110282. Filed: April 9, 2003. Lead Inventor: Yutaka Kanda, Kyowa Hakko Kogyo.
The patent application, its abstract states, covers the following: “A cell in which the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is more decreased or deleted than its parent cell; a process for producing an antibody composition using the cell; a transgenic non-human animal or plant or the progenies thereof, in which genome is modified so as to have a decreased or deleted activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body; a process for producing an antibody composition from the animal or plant; and a medicament comprising the antibody composition.”
The application also claims a cell in which “the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is decreased or deleted by a genetic engineering technique,” such as RNAi.